Adcendo ApS, a Danish company founded in 2017 to develop antibody-drug conjugate (ADC) technology, has raised €51 million in a Series A financing – the largest Series A round for a Danish biotech company. Adcendo is developing ADCs directed against a cell surface receptor which is understood to be overexpressed on several non-epithelial cancers including sarcomas, glioblastomas and subsets of acute myeloid leukaemia. Expression is restricted in healthy individuals.
